Full-Time

Bioinformatics Analyst

Confirmed live in the last 24 hours

Elegen

Elegen

51-200 employees

Custom DNA synthesis for biotech applications

Biotechnology
Healthcare

Compensation Overview

$125k - $150kAnnually

+ Bonus + Equity

Mid

San Carlos, CA, USA

Compensation for California is $125,000 - $150,000.

Category
Bioinformatics
Biology & Biotech
Required Skills
Python
Jupyter
SQL
AWS
Pandas
Data Analysis
Requirements
  • A bachelor’s degree or master’s degree with 3 years of experience in a related field such as computer science, molecular biology, biochemistry, genetics, genomics, or chemistry
  • Solid programming experience in SQL and Python
  • Extensive experience with Oxford Nanopore Technology (ONT)
  • Comfortable operating in cloud-based technologies such as AWS
  • Candidates will need to have experience retrieving, analyzing, and presenting process and product data for internal stakeholders
  • Strong interpersonal skills and the ability to work well in a team
  • Attention to detail and the ability to work efficiently in a fast-paced environment
  • Critical and strategic thinking in your work, including making logical conclusions, anticipating obstacles, and open-minded approaches to problem-solving
  • Experience in bioinformatics and using command-line tools
  • Excellent communication skills, both written and verbal
Responsibilities
  • Use industry-standard data-analysis tools to provide insights into our production processes to internal stakeholders (SQL, Python, Jupyter, Pandas, Seaborn, etc…).
  • Use state-of-the-art bioinformatics tools to investigate Oxford Nanopore sequencing data for potential process improvements(Dorado, Guppy, Samtools, minimap, etc…).
  • Develop APIs that provide data to our ETL and ensure the resulting data structures are well organized.
  • Create dashboards and reports to give the Executive Leadership Team visibility into our KPIs.
  • Work in tandem with R&D and manufacturing to solve problems and create new products with a data-first mindset.

Elegen focuses on improving the DNA manufacturing process within the synthetic biology sector. The company provides custom DNA synthesis services to researchers, biotech companies, and pharmaceutical firms that need high-quality synthetic DNA for applications like biomanufacturing and mRNA-based treatments. Elegen uses advanced technologies to ensure fast turnaround times and high accuracy in DNA synthesis, which are essential for its clients' projects. Unlike its competitors, Elegen not only streamlines traditional DNA manufacturing workflows but also enables the production of valuable biologics and small molecules. The company's goal is to support the growing bioeconomy by facilitating the development of advanced therapeutics and mRNA medicines.

Company Stage

Series B

Total Funding

$34M

Headquarters

San Carlos, California

Founded

2017

Growth & Insights
Headcount

6 month growth

33%

1 year growth

45%

2 year growth

141%
Simplify Jobs

Simplify's Take

What believers are saying

  • The recent $35M Series B funding, led by prominent investors like Triatomic Capital and GSK, will accelerate the expansion of Elegen’s ENFINIA™ DNA product line and enhance its clinical manufacturing capabilities.
  • Elegen's collaboration and licensing agreement with GSK to use their proprietary cell-free DNA manufacturing technology in developing vaccines and medicines highlights the company's potential for significant industry impact.
  • The commercial launch of the enhanced ENFINIA™ DNA, which offers highly complex DNA in as fast as 10 business days, positions Elegen as a leader in rapid and reliable DNA synthesis.

What critics are saying

  • The synthetic biology market is highly competitive, requiring Elegen to continuously innovate to maintain its edge.
  • Dependence on key partnerships, such as with GSK, could pose risks if these relationships were to change or dissolve.

What makes Elegen unique

  • Elegen's cell-free DNA manufacturing technology offers a significant advantage over traditional plasmid-based methods, reducing contamination risks and accelerating production timelines.
  • The company's ENFINIA™ DNA product line provides highly complex, NGS-verified DNA with rapid turnaround times, setting a new industry standard.
  • Elegen's Early Access Program fosters strong client relationships and provides an additional revenue stream by offering early access to their latest DNA breakthroughs.

Help us improve and share your feedback! Did you find this helpful?